Research News and Research

RSS

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

Free health clinics still drawing large crowds in cities across U.S.

Parade: A series of no-cost health care clinics are making their way across America. In Atlanta 1,050 volunteers gave their time to serve uninsured Americans who needed medical care. "The Atlanta mega-clinic was the sixth in a series that began in September. (The first was held in Houston in partnership with TV talk-show host and cardiothoracic surgeon Dr. Mehmet Oz.)

11 May 2010

Nuts added to unhealthy diets can still reduce cholesterol and benefit the heart

It has been known for a while now that eating nuts regularly offers cardiovascular benefits. Now a new study has established the fact that a regular intake of nuts can lead to better and healthier cholesterol levels.

10 May 2010

Genetic link to risk for diabetes and weight gain: New study

A recent study published in the international journal Diabetologia showed that Australians who eat too many high fat snacks tend to put on more weight if they have someone in their family with diabetes.

10 May 2010

Jubilant Organosys reports 17.7% increase in fourth-quarter consolidated revenue

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced its financial results for Q4 & FY2010.

10 May 2010

Behavioral economics tested in new health law

The new health law contains "many opportunities to nudge people toward better health choices. … 'In healthcare, for years and years and years there's been an interest in changing provider and consumer behavior,'" says Stanford professor Alan Garber. "What's new is that money is flowing into research on behavioral economics, and the government is getting involved, Garber and others said.

10 May 2010

Hospital operator HCA plans to offer $4.6 billion IPO

HCA Inc., the nation's biggest hospital operator by number of facilities, filed plans last week for a $4.6 billion initial public offering as it "looks to return to the public markets," The Wall Street Journal reports.

10 May 2010

Today's Opinions: The need for federal review of rate increases; Dems and GOP share blame for health costs; A phoney deal on Medicaid

This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).

10 May 2010

Takeda appoints BNY Mellon as depositary bank for sponsored ADR program

BNY Mellon, the global leader in asset management and securities servicing, has been appointed by Takeda Pharmaceutical Company Limited (Takeda) as the depositary bank for its sponsored American depositary receipt (ADR) program. Each Takeda ADR represents one-half of a common share and trades on the over-the-counter (OTC) market under the symbol TKPYY. Takeda's common shares trade on the Tokyo Stock Exchange as well as four other exchanges in Japan under the code "4502." Previously, Takeda traded as an unsponsored ADR program serviced by multiple depositaries.

10 May 2010

Companies get help to insure early retirees

Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.

10 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Companies await health IT windfall

The Washington Post: A Virginia firm, Vangent, is positioning "itself for a surge of federal spending on health information technology" by setting up a health IT strategy group. "Vangent is likely to face stiff competition for those dollars, but company officials say they expect the firm's reputation as a health-related services provider to serve it well as it bids on contracts." The firm is also involved in civil, defense and national security work, but health services are its largest business.

10 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010